Analytical Data
-
Gene name
NY-SAR-48
- Application
-
Alternative Names
DGT4; HAUS augmin like complex subunit 8; HAUS augmin-like complex subunit 8; HAUS8; HAUS8_HUMAN; Hec1 interacting and centrosome associated 1; HEC1/NDC80 interacting centrosome associated protein 1; HEC1/NDC80-interacting centrosome-associated protein 1; HICE 1; HICE1; MGC20533; NY SAR 48; NY-SAR-48; Sarcoma antigen NY SAR 48; Sarcoma antigen NY-SAR-48
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BT25
-
Expression Region
2-410 aa
-
AA Sequence
ADSSGRGAG KPATGPTNSS SAKKKDKRVQ GGRVIESRYL QYEKKTTQKA PAGDGSQTRG KMSEGGRKSS LLQKSKADSS GVGKGDLQST LLEGHGTAPP DLDLSAINDK SIVKKTPQLA KTISKKPEST SFSAPRKKSP DLSEAMEMME SQTLLLTLLS VKMENNLAEF ERRAEKNLLI MCKEKEKLQK KAHELKRRLL LSQRKRELAD VLDAQIEMLS PFEAVATRFK EQYRTFATAL DTTRHELPVR SIHLEGDGQQ LLDALQHELV TTQRLLGELD VGDSEENVQV LDLLSELKDV TAKKDLELRR SFAQVLELSA EASKEAALAN QEVWEETQGM APPSRWYFNQ DSACRESGGA PKNTPLSEDD NPGASSAPAQ ATFISPSEDF SSSSQAEVPP SLSRSGRDLS
-
Molecular Weight
44.8 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NY-SAR-48 is a recombinant protein that has garnered significant attention in cancer research, particularly for its potential as a targeted therapeutic agent. Initially discovered in the context of melanoma, NY-SAR-48 consists of a modified murine interleukin-2 (IL-2) fused with a single-chain variable fragment (scFv) derived from a tumor-specific antibody. This design aims to enhance the targeting of immune responses towards tumor cells while minimizing effects on healthy tissues. The background of this research is rooted in the need for more effective cancer treatments that can elicit strong immune responses specifically against cancer cells. Traditional therapies often come with severe side effects due to non-specific activity, leading to the exploration of more refined immunotherapeutic strategies. NY-SAR-48 is particularly interesting because it combines the potent immune-stimulating properties of IL-2 with the specificity of an antibody fragment, laying the groundwork for personalized cancer immunotherapy. In preclinical studies, NY-SAR-48 has shown promising results in activating T cells and enhancing anti-tumor immunity, indicating its potential role in combination with other treatments such as checkpoint inhibitors. Continued research is focused on elucidating its mechanisms of action, optimizing dosing regimens, and evaluating clinical efficacy through forthcoming trials. As such, NY-SAR-48 represents a significant advancement in the ongoing quest to develop more effective and safer therapeutic options for cancer patients.
